April 2, 2019

Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma

Key Points

Key points are not available for this paper at this time.

Abstract

Our data unveiled a new mechanism of alleviating IFNγ-induced PD-L1 and IDO1 expression and provided a rationale to explore a novel combination of ICB with regorafenib clinically, especially in melanoma with RET/Src axis activation.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Rui-Yan Wu

Pengfei Kong

Liang-Ping Xia

Journals

Clinical Cancer Research

Actions

Institutions

Sun Yat-sen University

Sun Yat-sen University Cancer Center

First Affiliated Hospital of Zhengzhou University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study